资讯
内科
心血管
肿瘤
内分泌
普通内科
消化
呼吸
神经科
传染科
精神心理
肾内科
风湿免疫
血液科
老年医学
外科
头颈外科
胃肠外科
血管外科
肝胆胰外
骨科
普通外科
胸心外科
神经外科
泌尿外科
烧伤科
整形美容
麻醉疼痛
专科科室
罕见病
康复医学
药械
儿科
耳鼻咽喉
口腔科
眼科
政策人文
营养全科
预防公卫
妇产科
中医科
急重症
皮肤性病
影像放射
转化医学
检验病理
护理
热点
临床研究
研究设计
人工智能
智慧医疗
论文基金
医学科普
药物经济
医生集团
职业安全
患者招募
医学科研
公司产业
医学英语
MedSci动态
指南
按科室浏览
肿瘤科
心血管
传染科
妇产科
神经科
儿科
呼吸
内分泌科
血液科
消化
更多科室
工具
临床工具
临床指南
医学计算与公式
ICD-10/ICD-11疾病编码
医讯达
直播
话题
公开课
精品课
科研工具
期刊数据库查询
期刊智能选择
全球基金查询
文献查询
SCI写作宝典
生物医药大词典
其他工具
下载App使用方便更快捷
Medsci 梅斯搜索
公开课
精品课
服务
科研数智化
直播,公开课与精品课
科研加速器
研究者发起的临床研究(IIS)支持
真实世界研究解决方案
药物经济学
医保准入事务
研究方案设计
数据库建立与管理
药物警戒(PV)
真实世界研究执行
数据统计分析
数字化学术传播解决方案
多渠道营销(MCM)
产品医学策略
学术传播(APO)
其它
积分商城
FAQS
map
#Nintedanib#
24篇内容 | 1623人围观
关注话题
话题活跃用户
#
插入话题
插入图片
评论
最新
最热
GetTopicDetailResponse(id=131d12808f9, topicName=Nintedanib, introduction=Nintedanib, content=null, image=null, comments=24, allHits=1623, url=https://h5.medsci.cn/topic?id=12808, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=11708, tagList=[TagDto(tagId=11708, tagName=Nintedanib)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1361798, encodeId=465e1361e9857, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=Clin Oncol:晚期肺腺癌二线免疫治疗进展后Nintedanib +多西他赛三线治疗的疗效, objectType=article, longId=301250, objectId=210e30125037, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=210e30125037, replyNumber=0, likeNumber=65, createdTime=2022-03-22, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=210e30125037, moduleTitle=Clin Oncol:晚期肺腺癌二线免疫治疗进展后Nintedanib +多西他赛三线治疗的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=210e30125037)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361797, encodeId=b5a21361e9714, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=Nintedanib治疗系统性硬化症相关性间质性肺病:已获得CHMP的积极评价, objectType=article, longId=189088, objectId=39b718908848, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39b718908848, replyNumber=0, likeNumber=70, createdTime=2020-03-03, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39b718908848, moduleTitle=Nintedanib治疗系统性硬化症相关性间质性肺病:已获得CHMP的积极评价, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=39b718908848)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361796, encodeId=5a841361e9681, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=Brit J Cancer:Nintedanib:肝内胆管癌的新福音——尼达尼布!, objectType=article, longId=187798, objectId=7c9018e79870, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c9018e79870, replyNumber=0, likeNumber=78, createdTime=2020-02-12, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c9018e79870, moduleTitle=Brit J Cancer:Nintedanib:肝内胆管癌的新福音——尼达尼布!, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7c9018e79870)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361795, encodeId=b7591361e955e, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=加拿大卫生部批准OFEV(nintedanib)用以缓解系统性硬化症相关ILD患者肺功能下降, objectType=article, longId=183715, objectId=fe2f183e1514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe2f183e1514, replyNumber=0, likeNumber=74, createdTime=2019-11-29, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe2f183e1514, moduleTitle=加拿大卫生部批准OFEV(nintedanib)用以缓解系统性硬化症相关ILD患者肺功能下降, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fe2f183e1514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361794, encodeId=b0bc1361e9482, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=NEJM:nintedanib可以减缓间质性肺病患者肺功能的下降, objectType=article, longId=180874, objectId=d8701808e4d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8701808e4d2, replyNumber=0, likeNumber=68, createdTime=2019-10-12, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8701808e4d2, moduleTitle=NEJM:nintedanib可以减缓间质性肺病患者肺功能的下降, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d8701808e4d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361793, encodeId=44171361e9302, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=2019年ERS:Nintedanib减慢纤维化间质性肺病的进展, objectType=article, longId=180637, objectId=7ff718063eac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ff718063eac, replyNumber=0, likeNumber=79, createdTime=2019-10-09, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ff718063eac, moduleTitle=2019年ERS:Nintedanib减慢纤维化间质性肺病的进展, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7ff718063eac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361792, encodeId=3dfd1361e9295, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=FDA批准nintedanib治疗与系统性硬化症相关的间质性肺病, objectType=article, longId=179152, objectId=816f1e9152ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=816f1e9152ed, replyNumber=0, likeNumber=81, createdTime=2019-09-10, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=816f1e9152ed, moduleTitle=FDA批准nintedanib治疗与系统性硬化症相关的间质性肺病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=816f1e9152ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361791, encodeId=226b1361e91ad, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=NEJM:Nintedanib治疗系统性硬化性间质性肺病, objectType=article, longId=174366, objectId=d34f1e436665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d34f1e436665, replyNumber=0, likeNumber=85, createdTime=2019-06-29, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d34f1e436665, moduleTitle=NEJM:Nintedanib治疗系统性硬化性间质性肺病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d34f1e436665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361790, encodeId=f2411361e901d, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=NEJM:Nintedanib系统性硬化相关的肺间质疾病的效果, objectType=article, longId=168676, objectId=cd361686e684, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd361686e684, replyNumber=0, likeNumber=75, createdTime=2019-06-19, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd361686e684, moduleTitle=NEJM:Nintedanib系统性硬化相关的肺间质疾病的效果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cd361686e684)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361789, encodeId=99c21361e899d, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=ANN ONCOL:Nintedanib治疗难治性转移性结直肠癌, objectType=article, longId=149951, objectId=509f149951c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=509f149951c3, replyNumber=0, likeNumber=75, createdTime=2018-09-30, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=509f149951c3, moduleTitle=ANN ONCOL:Nintedanib治疗难治性转移性结直肠癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=509f149951c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361788, encodeId=08971361e882f, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=nintedanib对恶性胸膜间皮瘤的有效性, objectType=article, longId=138660, objectId=4ae8138660ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ae8138660ec, replyNumber=0, likeNumber=62, createdTime=2018-05-22, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ae8138660ec, moduleTitle=nintedanib对恶性胸膜间皮瘤的有效性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4ae8138660ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361787, encodeId=53a71361e8720, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=BI:Ofev®(nintedanib,尼达尼布)治疗特发性肺纤维化表现出持续长期疗效, objectType=article, longId=122647, objectId=9b3f12264ea6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b3f12264ea6, replyNumber=0, likeNumber=68, createdTime=2017-12-09, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b3f12264ea6, moduleTitle=BI:Ofev®(nintedanib,尼达尼布)治疗特发性肺纤维化表现出持续长期疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9b3f12264ea6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361786, encodeId=a7451361e8614, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=勃林格血管激酶抑制剂Ofev(nintedanib)在欧美喜获治疗系统性硬化症(SSc)的孤儿药地位, objectType=article, longId=77494, objectId=d3b3e749422, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3b3e749422, replyNumber=0, likeNumber=54, createdTime=2016-09-16, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3b3e749422, moduleTitle=勃林格血管激酶抑制剂Ofev(nintedanib)在欧美喜获治疗系统性硬化症(SSc)的孤儿药地位, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d3b3e749422)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361785, encodeId=12ef1361e85b0, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=Lancet Oncol:标准一线化疗方案加Nintedanib治疗晚期卵巢癌效果显著, objectType=article, longId=58865, objectId=72f55886548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72f55886548, replyNumber=0, likeNumber=72, createdTime=2015-11-18, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72f55886548, moduleTitle=Lancet Oncol:标准一线化疗方案加Nintedanib治疗晚期卵巢癌效果显著, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=72f55886548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361784, encodeId=8d8a1361e8484, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=Respir Res:尼达尼布(nintedanib)对特发性肺纤维化长期有效性且安全性良好(INPULSIS-ON试验), objectType=article, longId=57387, objectId=bf105e387d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf105e387d9, replyNumber=0, likeNumber=87, createdTime=2015-10-19, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf105e387d9, moduleTitle=Respir Res:尼达尼布(nintedanib)对特发性肺纤维化长期有效性且安全性良好(INPULSIS-ON试验), moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bf105e387d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361783, encodeId=86821361e83b1, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=勃林格启动抗癌药nintedanib结直肠癌全球III期研究, objectType=article, longId=41705, objectId=0fbd41e05ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fbd41e05ec, replyNumber=0, likeNumber=72, createdTime=2014-10-26, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fbd41e05ec, moduleTitle=勃林格启动抗癌药nintedanib结直肠癌全球III期研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0fbd41e05ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361782, encodeId=176c1361e82a6, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=FDA同时批准罗氏Pirfenidone和BI的Nintedanib, objectType=article, longId=41401, objectId=a80241401dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a80241401dd, replyNumber=0, likeNumber=76, createdTime=2014-10-19, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a80241401dd, moduleTitle=FDA同时批准罗氏Pirfenidone和BI的Nintedanib, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a80241401dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361781, encodeId=76d51361e8183, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=FDA授予勃林格殷格翰激酶抑制剂nintedanib突破性疗法认定, objectType=article, longId=38055, objectId=fc3c38055d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc3c38055d3, replyNumber=0, likeNumber=65, createdTime=2014-07-23, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc3c38055d3, moduleTitle=FDA授予勃林格殷格翰激酶抑制剂nintedanib突破性疗法认定, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fc3c38055d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361780, encodeId=53bc1361e800d, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=勃林格肺纤维化药物Nintedanib获FDA突破性治疗药物资格, objectType=article, longId=38021, objectId=0ab338021cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ab338021cd, replyNumber=0, likeNumber=92, createdTime=2014-07-20, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ab338021cd, moduleTitle=勃林格肺纤维化药物Nintedanib获FDA突破性治疗药物资格, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0ab338021cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1361779, encodeId=90131361e7985, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, objectTitle=NEJM:Nintedanib对特发性肺纤维化安全有效(INPULSIS试验)?, objectType=article, longId=36439, objectId=b4a0364396f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4a0364396f, replyNumber=0, likeNumber=73, createdTime=2014-06-17, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4a0364396f, moduleTitle=NEJM:Nintedanib对特发性肺纤维化安全有效(INPULSIS试验)?, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b4a0364396f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯话题小助手
关注
已关注
Nintedanib
2020-05-29
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
Clin Oncol:晚期肺腺癌二线免疫治疗进展后Nintedanib +多西他赛三线治疗的疗效
65
0
2022-03-22
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
Nintedanib治疗系统性硬化症相关性间质性肺病:已获得CHMP的积极评价
70
0
2020-03-03
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
Brit J Cancer:Nintedanib:肝内胆管癌的新福音——尼达尼布!
78
0
2020-02-12
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
加拿大卫生部批准OFEV(nintedanib)用以缓解系统性硬化症相关ILD患者肺功能下降
74
0
2019-11-29
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
NEJM:nintedanib可以减缓间质性肺病患者肺功能的下降
68
0
2019-10-12
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
2019年ERS:Nintedanib减慢纤维化间质性肺病的进展
79
0
2019-10-09
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
FDA批准nintedanib治疗与系统性硬化症相关的间质性肺病
81
0
2019-09-10
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
NEJM:Nintedanib治疗系统性硬化性间质性肺病
85
0
2019-06-29
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
NEJM:Nintedanib系统性硬化相关的肺间质疾病的效果
75
0
2019-06-19
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
ANN ONCOL:Nintedanib治疗难治性转移性结直肠癌
75
0
2018-09-30
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
nintedanib对恶性胸膜间皮瘤的有效性
62
0
2018-05-22
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
BI:Ofev®(nintedanib,尼达尼布)治疗特发性肺纤维化表现出持续长期疗效
68
0
2017-12-09
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
勃林格血管激酶抑制剂Ofev(nintedanib)在欧美喜获治疗系统性硬化症(SSc)的孤儿药地位
54
0
2016-09-16
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
Lancet Oncol:标准一线化疗方案加Nintedanib治疗晚期卵巢癌效果显著
72
0
2015-11-18
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
Respir Res:尼达尼布(nintedanib)对特发性肺纤维化长期有效性且安全性良好(INPULSIS-ON试验)
87
0
2015-10-19
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
勃林格启动抗癌药nintedanib结直肠癌全球III期研究
72
0
2014-10-26
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
FDA同时批准罗氏Pirfenidone和BI的Nintedanib
76
0
2014-10-19
回复
仁者大医
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
FDA授予勃林格殷格翰激酶抑制剂nintedanib突破性疗法认定
65
0
2014-07-23
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
勃林格肺纤维化药物Nintedanib获FDA突破性治疗药物资格
92
0
2014-07-20
回复
xiongke010
(审核中...)
关注
已关注
前往app查看评论内容
#Nintedanib#
NEJM:Nintedanib对特发性肺纤维化安全有效(INPULSIS试验)?
73
0
2014-06-17
回复
共24条
首页
上一页
下一页
尾页
页码:
1
/2页
20条/页
扫描二维码下载梅斯医学APP
map
科室
订阅+
更多科室
工具
服务
map
map